Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

Akira Ono1*, Toshiaki Takahashi1, Keita Mori4, Hiroaki Akamatsu1, Takehito Shukuya1, Tetsuhiko Taira1, Hirotsugu Kenmotsu1, Tateaki Naito1, Haruyasu Murakami1, Takashi Nakajima2, Masahiro Endo3 and Nobuyuki Yamamoto1

Abstract

Background: Serum CYFRA 21–1 is one of the most important serum markers in the diagnosis of non-small cell lung cancer (NSCLC), especially squamous-cell carcinoma. However, it remains unknown whether pretreatment serum CYFRA 21–1 values (PCV) may also have prognostic implications in patients with advanced lung adenocarcinoma.

Methods: We retrospectively reviewed the data of 284 patients (pts) who were diagnosed as having advanced lung adenocarcinoma and had received initial therapy.

Results: Of the study subjects, 121 pts (43%) had activating epidermal growth factor receptor (EGFR) mutations (Mt+), while the remaining 163 pts (57%) had wild-type EGFR (Mt-). Univariate analysis identified gender (male/ female), ECOG performance status (PS) (0-1/ ≥2), PCV (<2.2 ng/ml/ ≥2.2 ng/ml), EGFR mutation status (Mt+/ Mt-), pretreatment serum CEA values (<5.0 ng/ml/ ≥5.0 ng/ml), smoking history (yes/ no) and EGFR-TKI treatment (yes/ no) as prognostic factors (p = .008, p < .0001, p < .0001, p < .0001, p = .036, p = .0012, p < .0001 respectively). Cox’s multivariate regression analysis identified PCV < 2.2ng/ml as the only factor significantly associated with prolonged survival (p < .0001, hazard ratio: 0.43, 95% CI 0.31-0.59), after adjustments for PS (p < .0001), EGFR mutation status (p = .0069), date of start of initial therapy (p = .07), gender (p = .75), serum CEA level (p = .63), smoking history (p = .39) and EGFR-TKI treatment (p = .20). Furthermore, pts with Mt+ and PCV of <2.2 ng/ml had a more favorable prognosis than those with Mt+ and PCV of ≥2.2 ng/ml (MST: 67.0 vs. 21.0 months, p < .0001), and patients with Mt- and PCV of <2.2 ng/ml had a more favorable prognosis than those with Mt- and PCV of ≥2.2 ng/ml (MST: 24.1 vs. 10.2 months, p < .0001).

Conclusion: PCV may be a potential independent prognostic factor in both Mt+ and Mt- patients with advanced lung adenocarcinoma.

Keywords: Lung adenocarcinoma, Prognostic factor, CYFRA 21–1, CEA, EGFR mutation, Tumor heterogeneity, EGFR-TKI, Chemotherapy

* Correspondence: a.ono@scchr.jp
1Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagazumi-cho, Sunto-gun, Shizuoka 411-8777, Japan
Full list of author information is available at the end of the article

© 2013 Ono et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

Lung cancer is the leading cause of cancer death, and at present, there exists no cure of stage IV non-small cell lung cancer (NSCLC) [1]. Adenocarcinoma and squamous cell carcinoma are the most common histological subtypes of lung cancer and account for about 70% of all lung cancers [2]. The folate antagonist pemetrexed has been shown to exhibit efficacy against non-squamous cell lung cancers [3], and is currently used in combination with cisplatin as a standard treatment regimen for patients with non-squamous cell lung carcinoma. Chemotherapy with the angiogenesis inhibitor bevacizumab administered in combination with platinum agents has also been shown to exhibit favorable efficacy against non-squamous cell lung carcinoma [4,5]. Somatic gain-of-function mutations in exons encoding the EGFR tyrosine kinase domain have been identified in NSCLC [6,7]. Several previous studies have reported prolongation of the survival time in patients with EGFR-mutation-positive lung carcinomas treated with EGFR-tyrosine kinase inhibitors (TKIs) [8-11], therefore, EGFR-TKIs are widely used in medical practice. EGFR mutations occur more frequently in lung cancer patients who are Asians, females and non-smokers with the histological subtype of adenocarcinoma [12-14]. On the other hand, while there have also been scattered reports of EGFR mutations among cases of lung squamous-cell carcinoma [15-17], a recent report showed that there were no EGFR mutation-positive cases among lung cancer patients with pure squamous cell carcinoma [18,19].

CYFRA 21–1 is a fragment of cytokeratin (CK) 19. CKs, which are now called keratins, are the principal structural elements of the cytoskeleton (keratin filaments) of epithelial cells, including bronchial epithelial cells, and have been classified into 20 subtypes based on differences in the molecular mass and isoelectric point as determined by 2-dimensional electrophoresis [20,21]. CK types 1–8 are categorized as type I CKs, and CKs 9–20 as type II CKs. Microfilaments are heteropolymers formed from type I and type II keratins, and constitute the cytoskeleton [22]. CK19 is a soluble type I CK (acidic type), and has the lowest molecular mass (40 kDa) among the CKs. It is expressed in the unstratified or pseudostratified epithelium lining the bronchial tree [23], and been reported to be overexpressed in many lung cancer tissue specimens [24]. The CK expression patterns in tissues are well-maintained even during the process of transformation of the tissue from normal to tumor tissue [25]. Accelerated CK19 degradation occurs in neoplastically transformed epithelial cells as a result of increased protease activity of caspase 3, a regulator of the apoptosis cascade, and fragments are released into the blood. This results in an increase of the blood CYFRA 21–1 values, because CK19 fragments are recognized by two monoclonal antibodies [26].

Measurement of serum CYFRA 21–1 level is a useful auxiliary test in the diagnosis of NSCLC, and particularly high specificity of this test has been reported for the diagnosis of squamous cell carcinoma of the lung [27,28]. On the other hand, a meta-analysis also revealed that serum CYFRA 21–1 may be a useful prognostic factor in NSCLC patients [29]; analysis of the histological background in the aforementioned meta-analysis showed that non-adenocarcinoma accounted for the majority of cases of NSCLC (65%). There has also been a report suggesting that serum CYFRA 21–1 levels might serve as a prognostic factor in patients with recurrent NSCLC receiving 3rd-line or later gefitinib therapy [30]. Some studies have suggested the possible prognostic value of pretreatment serum CYFRA 21–1 values (PCV) in patients with surgically treated lung adenocarcinoma [31] and advanced NSCLC [32-34]. However, none of the studies suggesting serum CYFRA 21–1 as a prognostic factor in patients with untreated advanced lung adenocarcinoma has included the EGFR mutation status as a variable. Therefore, in the present study, we investigated the impact of serum CYFRA 21–1 on the prognosis of untreated advanced lung adenocarcinoma patients.

Methods

Patients

Of patients diagnosed as having primary lung carcinoma between January 2003 and June 2010 at the Shizuoka Cancer Center, EGFR mutation analysis was performed on 424 patients from April 2008 to June 2010. Of these, 284 lung adenocarcinoma patients had received initial therapy, and we retrospectively reviewed the data of the 163 patients who were found to harbor wild-type EGFR and 121 patients who were found to harbor activating EGFR mutations (Figure 1). The following inclusion criteria were set for this study; patients with pathologically proven adenocarcinoma who had received initial therapy (including chemotherapy or chemoradiotherapy) and survived for more than one month; Eastern Cooperative Oncology Group performance status (ECOG PS) of 3 or less. The histological and cytological diagnoses were performed according to the WHO classification criteria [35]. The study was conducted with the approval of the Shizuoka cancer center Institutional Review Board #1 (HHS IRB registration number; IRB00006744).

We outsourced some of the clinical laboratory tests, such as measurement of the tumor markers and EGFR mutation analysis. Serum CYFRA 21–1 and serum CEA concentrations were measured at the baseline, before the initial therapy. The serum CYFRA 21–1 concentration was measured using a Lumipulse Presto® kit (FUJIREBIO Inc, Tokyo, Japan), based on a CLEIA (chemiluminescent enzyme immunoassay) method, while the serum CEA concentrations were measured using an ARCHITECT® kit.
EGFR mutation analysis was performed by fragment analysis using polymerase chain reaction (PCR) and the cycleave real-time quantitative PCR technique (SRL Inc, Tokyo, Japan).

The reported upper limit of normal for the diagnosis of NSCLC and upper limit of the percentiles for healthy individuals of serum CYFRA 21–1 as measured by EIA are 3.5 ng/ml and 2.8 ng/ml, respectively [36]. In contrast, the reported upper limit of the percentiles for healthy individuals of serum CYFRA 21–1 measured by the CLEIA method is 1.6 ng/ml [37], a lower value as compared to that set for measurement by the EIA method. Therefore, for our study, we set the cutoff value for CYFRA 21–1 at 2.2 ng/ml, which is the upper limit of normal.

A standard evaluation of the patients, including assessment of the medical history, physical examination and routine laboratory tests, was performed before each treatment. All patients were staged based on the International Association for the Study of Lung Cancer (IASLC) TNM (tumor-node-metastasis) classification, 7th edition [38].

Statistical methods
There were no missing data in our study. Survival was estimated using the Kaplan-Meier method. Overall survival was measured from the date of the first course of the initial therapy to the date of death or that of the last follow-up examination. A log-rank test was performed to evaluate the significance of differences in the overall survival among the groups. P values < 0.05 were considered to be indicative of statistical significance. A multivariate analysis using the Cox proportional hazards model was used to establish the association between the clinical variables and survival. All statistical analyses were carried out using SPSS, version 11.0 for Windows (SPSS Inc., Chicago, IL, USA). To reduce the potential bias arising from some patients dying too early to receive initial therapy, the two patients who died within a month (30 days) of the start of initial therapy were excluded from the analysis.

Results
The cohort consisted of 284 patients who were diagnosed as having stage IIIB or IV lung adenocarcinoma and had received initial therapy.

The clinical characteristics of the patients are summarized in Table 1. The median patient age prior to the start of initial therapy was 65 years (range, 23 to 87 years). The patients were predominantly younger than 70 years of age (81%), the ECOG PS was 0–2 in 93% of patients, and 91% of the patients had stage IV disease. While the lung adenocarcinoma patients with EGFR mutations were predominantly female (64%) and non-smokers
(71%), those with wild-type EGFR were predominantly male (77%) and smokers (76%).

Details about the first-line chemotherapy were available for 284 patients including both patient groups with wild-type (Mt-) and mutant EGFR (Mt+) groups (Table 2). About 40% of the EGFR mutation-positive patients received EGFR-TKIs as the initial treatment. Carboplatin-paclitaxel, the treatment of choice across both groups, was administered to half of the platinum doublet cohort in the Mt- patient group. Meanwhile, docetaxel was administered to half of the monotherapy cohort in the same patient group. However, cisplatin-pemetrexed was the most common regimen of second choice across both the Mt+ and Mt- groups.

The EGFR-TKI used for each treatment line in the Mt+ group is shown in Table 3. Forty-one (58%) patients received gefitinib, while 16 (22%) received erlotinib as first-or second-line treatment in the Mt+ group with PCV (<2.2 ng/ml). Thirty-seven (73%) patients received gefitinib, and 10 (20%) patients received erlotinib as first-or second-line treatment in the Mt+ group with PCV (≥2.2 ng/ml). Of the 121 patients in the Mt+ group, 27 did not receive gefitinib at any treatment-line stage of treatment; among these 27 patients, 19 received erlotinib (6 as first-line, 10 as second-line, 1 as third-line and 2 as further-line treatment). In the Mt+ group, a total of 113 patients (93%) received EGFR-TKIs, while 8 patients did not receive EGFR-TKIs at any stage of treatment.

| Characteristic                | Mt+ (n= 121) | Mt- (n= 163) | All (n= 284) |
|-----------------------------|-------------|-------------|-------------|
| No. %                       | No. %       | No. %       |
| Age, years                  |             |             |             |
| Median (range) 66 (32–87)   | 65 (23–83)  | 65 (23–87)  |
| < 70                        | 97 (80)     | 134 (82)    | 231 (81)    |
| ≥ 70                        | 24 (20)     | 29 (18)     | 53 (19)     |
| Gender                      |             |             |             |
| Male 43 (36)                | 125 (77)    | 168 (59)    |
| Female 78 (64)              | 38 (23)     | 116 (41)    |
| ECOG PS                     |             |             |             |
| 0-1                         | 103 (85)    | 135 (83)    | 238 (84)    |
| > 2                         | 18 (15)     | 28 (17)     | 46 (16)     |
| Smoking status              |             |             |             |
| Yes 50 (41)                 | 124 (76)    | 174 (61)    |
| No 71 (59)                  | 39 (24)     | 110 (39)    |
| Stage                       |             |             |             |
| III/IV                      |              |             |             |
| Exon 19 deletion            | 59 (49)     | 59 (21)     |
| Exon 21 L858R               | 57 (47)     | 57 (20)     |
| Exon 18 G719X               | 5 (4)       | 5 (2)       |
| Wild type                   | 163 (100)   | 163 (57)    |
| PCV                         |             |             |             |
| Median (range) 1.6 (0.1–110.0) | 2.3 (0.1–80.0) | 2.0 (0.1–110.0) |
| < 2.2 ng/ml                 | 72 (60)     | 78 (48)     | 150 (53)    |
| ≥ 2.2 ng/ml                 | 49 (40)     | 85 (52)     | 134 (47)    |
| CEA                         |             |             |             |
| Median (range) 8 (0.7–11942) | 7 (0.5–14985) | 7.4 (0.5–14985) |
| < 5.0 ng/ml                 | 45 (37)     | 63 (39)     | 108 (38)    |
| ≥ 5.0 ng/ml                 | 76 (63)     | 100 (61)    | 176 (62)    |

EGFR: epidermal growth factor receptor, Mt+: mutant EGFR, Mt-: wild-type EGFR, PCV: pretreatment CYFRA 21-1 value.
Furthermore, of the 160 patients in the Mt- group, 30 patients received EGFR-TKIs (11 as second-line, 7 as third-line, 6 as fourth-line, 3 as fifth-line, 1 as sixth-line, 1 as seventh-line, and 1 as eighth-line treatment). Fifty-three patients (18%) were still alive at the time of the analysis. The median follow-up period for determining the survival was 39.3 (range; 11.8-84.9) months after the start of initial therapy. The clinical variables identified by univariate analysis to be associated with significantly better survival (Table 4) included female gender (MST 32.4 months versus 20.1 months in males: \( p = .0086 \)), no smoking history (33.4 months versus 20.1 months in smokers, \( p = .0012 \)), ECOG PS (0–1) (29.5 months versus 7.9 months in those with a PS of 2–3, \( p < .0001 \)), presence of EGFR mutation (39.2 months versus 17.8 months in patients without EGFR mutations, \( p < .0001 \)), PCV < 2.2 ng/ml (38.6 months versus 15.0 months in those with PCV ≥ 2.2 ng/ml, \( p < .0001 \)), serum CEA < 5.0 ng/ml (32.6 months versus 21.0 months in those with serum CEA ≥ 5.0 ng/ml, \( p = .036 \)), start date of initial therapy before April 1, 2008 (34.1 months versus 19.3 months in the group that received the initial therapy after April 1, 2008, \( p = .003 \)) and EGFR-TKI treatment (33.7 months versus 15.3 months in the group not treated with EGFR-TKIs, \( p < .0001 \)). Multivariate analysis identified EGFR mutation positivity (HR 0.53; 95% CI: 0.34-0.84, \( p = .0069 \)) and PCV < 2.2 ng/ml (HR 0.43; 95% CI: 0.31-0.59, \( p < .0001 \)) as independent favorable prognostic factors. Another factor that was found to be an independent prognostic indicator of overall survival was the PS (Table 4). The overall survival rates of patients with advanced lung adenocarcinoma with/ without EGFR mutation are shown in Figure 2. Among the Mt+ patients, the prognosis was more favorable in the group with PCV < 2.2 ng/ml (n = 70) than in the group with PCV ≥ 2.2 ng/ml (n = 48) (MST: 67.0 vs. 21.0 months, \( p < 0.0001 \)). Among the patients with Mt- also, the prognosis was more favorable in the group with PCV < 2.2 ng/ml (n = 78) than in the group with PCV ≥ 2.2 ng/ml (n = 86) (MST: 24.1 vs. 10.2 months, \( p < 0.0001 \)).

### Discussion

In the present study, we demonstrated PCV and EGFR mutation status as independent prognostic factors in untreated advanced lung adenocarcinoma patients. We also showed that PCV < 2.2 ng/ml was a predictor of a favorable outcome in both advanced lung adenocarcinoma patients with wild-type and mutant EGFR.

Serum CYFRA 21–1 has been reported as a prognostic factor in patients with a variety of cancer types, including resectable NSCLC [39,40], biliary tract cancer [41], urothelial cancer [42], head and neck cancer [43], esophageal cancer [44], and cervical cancer [45]. A meta-analysis of CYFRA 21–1 as a prognostic indicator in advanced NSCLC patients showed that the PCV may be a reliable prognostic factor [29], however, since non-adenocarcinoma accounted for 65% of the cases and squamous cell carcinoma for 50%, the role of serum CYFRA 21–1 as a prognostic indicator in the lung adenocarcinoma population remained unclear. Moreover, in a study of PCV as a prognostic indicator in advanced NSCLC patients in whom gefitinib was used as 3rd line or later therapy, adenocarcinoma accounted for fewer than a half of the cases (47%) [30]. The EGFR mutation status was not included as a variable in the analysis, and the test population was small, consisting of only 50 patients.

### Table 2 Summary of initial treatment delivered among 284 patients

| EGFR mutation | Mt- (n= 163) | Mt+ (n= 121) |
|---------------|-------------|-------------|
|               | IIIB (n= 19) | IV (n= 144) | IIIB (n= 6) | IV (n= 115) |
| Treatment     | No. %       | No. %       | No. %       | No. %       |
| Platinum doublet | 4 3 114 70 2 2 54 45 |
| Monotherapy   | 0 30 18 0 11 9 |
| EGFR-TKI      | 0 0 0 0 50 41 |
| Chemoradiotherapy | 15 9 0 4 3 0 |

### Table 3 Summary of EGFR-TKI delivered among EGFR mutation positive patients

| EGFR mutation positive | Low PCV (< 2.2 ng/ml) (n= 72) | High PCV (≥ 2.2 ng/ml) (n= 49) |
|------------------------|-------------------------------|---------------------------------|
|                        | Gefitinib | Erlotinib | Gefitinib | Erlotinib |
|                        | No. %     | No. %     | No. %     | No. %     |
| First-line             | 20 28 5 7 | 23 47 2 4 |
| Second-line            | 21 29 11 15 | 14 29 8 16 |
| Third-line             | 9 12 6 8 | 3 6 4 8 |
| Further-line           | 2 3 14 20 | 2 4 4 8 |
| Unadministered         | 20 28 36 50 | 7 14 31 63 |

PCV: pretreatment CYFRA 21–1 value.
Several factors may have contributed to identification of serum CYFRA 21–1 as a prognostic indicator in the advanced lung adenocarcinoma population in the present study. First, there could be a relationship between the serum levels of CYFRA 21–1 and the microfilament formation trend in the tumor cells [22]. CKs are the principal structural elements of intracellular microfilaments. Microfilaments have been shown to be heteropolymers formed from type I and type II keratins which form the cytoskeleton. Moreover, while the CKs (CKs 1, 2, 10/11), on which the degree of keratinization within tumors depends, are strongly expressed in well-differentiated squamous cell carcinomas, they are not detected in the serum. The possibility that they are preferentially removed by macrophages because of their poor solubility has been suggested as the reason for the failure to detect them in the serum [46]. By contrast, soluble CK19 is degraded by tumor lysis and tumor necrosis and released into the blood. Therefore, serum levels of CK19 may indicate the degree of cytoskeleton formation by microfilaments within the tumor cells. Second, there may also be a relationship between serum CYFRA 21–1 levels and the degree of tumor differentiation towards squamous epithelium. CKs with a relatively high molecular mass tend to be associated with differentiation into squamous cell carcinoma, while CKs with a relatively low molecular mass tend to be associated with differentiation into adenocarcinoma [47].

| Variable                                | No. | Univariate analysis (MST (months)) | Multivariate analysis (OR 95% CI) |
|-----------------------------------------|-----|-----------------------------------|----------------------------------|
| **Age**                                 |     |                                   |                                  |
| < 70                                    | 231 | 22.8                              | < .0001                          |
| > 70                                    | 53  | 24.3                              | 0.625                            |
| **Gender**                              |     |                                   |                                  |
| Male                                    | 168 | 20.1                              |                                  |
| Female                                  | 116 | 32.4                              | < .0001                          |
| **Smoking status**                      |     |                                   |                                  |
| Yes                                     | 174 | 20.1                              |                                  |
| No                                      | 110 | 33.4                              | 0.0012                           |
| **ECOG PS**                             |     |                                   |                                  |
| 0-1                                     | 238 | 29.5                              | < .0001                          |
| >2                                      | 46  | 7.9                               | PS 0-1                           |
| **Stage**                               |     |                                   |                                  |
| IIB                                     | 25  | 30.2                              |                                  |
| IV                                      | 259 | 22.5                              | 0.269                            |
| **EGFR mutation**                       |     |                                   |                                  |
| Mt (+)                                  | 121 | 39.2                              |                                  |
| Mt (−)                                  | 163 | 17.8                              | < .0001                          |
| **PCV**                                 |     |                                   |                                  |
| < 2.2 ng/ml                             | 150 | 38.6                              |                                  |
| ≥ 2.2 ng/ml                             | 134 | 15.0                              | < .0001                          |
| **CEA**                                 |     |                                   |                                  |
| < 5.0 ng/ml                             | 108 | 32.6                              |                                  |
| ≥ 5.0 ng/ml                             | 176 | 21.0                              | < 2.2 ng/ml                      |
| **Start dates of IT**                   |     |                                   |                                  |
| Before 1/4/2008                         | 79  | 34.1                              | After 1/4/2008                   |
| After 1/4/2008                          | 205 | 19.3                              | < .00030                         |
| **EGFR-TKI treatment**                  |     |                                   |                                  |
| Yes                                     | 143 | 33.7                              | < .0001                          |
| No                                      | 141 | 15.3                              | Yes                              |

IT: initial therapy, PCV: pretreatment CYFRA 21–1 value, Mt(+): mutant EGFR, Mt(−): wild-type EGFR.
which monoclonal antibodies were used, the number of cells containing CK19 increased with decreasing degree of differentiation into squamous cell carcinoma, and the presence of intracellular CK19 was consistently demonstrated in pure lung adenocarcinomas [25]. On the other hand, a negative correlation between intracellular CK19 expression and serum CYFRA 21–1 levels has also been shown [24]. Increase in the serum level of CYFRA 21–1 may also be the result of a greater degree of degradation and release of intracellular CK19 into the serum with an increasing tendency towards differentiation into squamous cell carcinoma.

Because identical EGFR mutations have been seen in both the adenocarcinoma component and squamous cell carcinoma component in resected cases of adenosquamous carcinoma [48], it has been suggested that the two components may arise from a single clone [48,49]. Resected cases of adenosquamous carcinoma have been reported to account for 3% of all cases of NSCLC [50], and adenosquamous carcinoma patients have also been reported to have a poor prognosis [51]. The prognosis of patients in whom the tumor tissue consists of a mixture of mutant EGFR cells and wild-type EGFR cells has been reported to be inferior to that of patients with tumors consisting of only mutant EGFR cells, and intratumor heterogeneity has also been investigated [52]. On the other hand, there is a report suggesting that no intratumor heterogeneity of EGFR expression is found in mutant EGFR lung adenocarcinomas, and also that no disparity is found between the EGFR mutation status of the primary tumor and lymph node metastasis [53].

There are several limitations of the present study. The first is that it was a retrospective study conducted at a single institution, and the possibility of a selection bias is undeniable. The prognosis of patients who received initial therapy before April 1, 2008 was significantly superior to that of those who received their initial therapy after 2008. Because we started to perform EGFR mutation analysis in routine clinical practice from April 1, 2008, there is the possibility of a selection bias towards patients who received the initial therapy before April 1, 2008. This is one of the major limitations of our retrospective study. Some studies have reported that EGFR mutations may be a positive prognostic factor for survival in advanced NSCLC patients, regardless of EGFR-TKI therapy [54,55]. Also in the BR.21 trial, the median survival time was reported to be longer in patients with mutant EGFR as compared to that in patients with wild-type EGFR [56]. Although mutant EGFR patients not treated with EGFR-TKIs were found to be a confounding factor, we performed adjustment for the confounding factor using a Cox proportional hazards model. According to the univariate analysis, the date of start of the initial therapy (before April 1, 2008) was a favorable prognostic factor. However, PCV < 2.2 ng/ml, EGFR mutation positivity and PS 0–1 were found to be independent favorable prognostic factors after adjustment for the date of start of the initial therapy. In this study, while the MST (39.2 months) in the mutant EGFR group was not favorable as compared to previous reports [57], the mutant EGFR group with PCV < 2.2 ng/ml had a more favorable prognosis than that of the mutant EGFR group with PCV ≥ 2.2 ng/ml. The proportion of patients who received erlotinib was less in the group with PCV ≥ 2.2 ng/ml than in the group with PCV < 2.2 ng/ml, which could have influenced the more favorable prognosis in the group with PCV < 2.2 ng/ml than in the group with PCV ≥ 2.2 ng/ml. All of the patients with advanced lung adenocarcinoma in whom the diagnosis was made after April 1, 2008 were tested for EGFR mutations at
the time of the diagnosis, whereas in the patients with other histological types of lung cancer, the testing was performed at the discretion of the attending physician. Second, the follow-up period was inadequate, especially in the mutant EGFR group with PCV < 2.2 ng/ml, and the censored cases were conspicuous. There was also a problem with the stage distribution (there were relatively few stage IIIB cases). Distant metastasis occurred in all of the stage IIIB cases in which local treatment had been performed, and all of the patients with disease recurrence were tested for EGFR mutations. Moreover, significant survival differences in stage III/IV were not found in the univariate analysis. Furthermore, the treatment regimens used in the stage IV cases were not standardized, with each of the attending physicians administering any of the various standard treatments used in routine clinical practice recommended by the guidelines of the Japan Lung Cancer Society.

In advanced lung adenocarcinoma, which may be considered as a generalized systemic disease, it may be particularly difficult to determine the characteristics of an entire heterogeneous tumor by tissue diagnosis alone based on examining just one part of the tumor. Based on the results of the present study, we propose that mutant EGFR patients with serum PCV < 2.2 ng/ml have a better prognosis than the mutant EGFR patients with higher PCV.

Conclusions

The potential applications of PCV measurements might include identification of candidates in whom it might have some prognostic value. Furthermore, PCV might be regarded as a routine demographic variable having prognostic value in patients with advanced lung adenocarcinoma.

Abbreviations

NSCLC: Non-small cell lung cancer; PCV: Pretreatment serum CYFRA 21–1 levels; pts: patients; EGFR: Epidermal growth factor receptor; Mt+: Mutant EGFR; Mr-: Wild-type; TKI: Tyrosine kinase inhibitor; CK: Cytokeratin; ECOG PS: Eastern Cooperative Oncology Group performance status; CLEA: Chemiluminescence enzyme immunoassay; PCR: Polymerase chain reaction; IASLC: International Association of the Study of Lung Cancer; TNM: Tumor-node-metastasis.

Competing interests

The authors have no competing interests to declare.

Authors’ contributions

AO contributed to the drafting of this manuscript and data collection, and KM contributed to the study design and statistical analysis. TT, HA, TS, TK, TN, HM, TN, ME, NY contributed to analysis of the data and interpretation of the findings. All authors have read and approved of the submission of the final manuscript.

Author details

1Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonakakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
2Division of Diagnostic Pathology, Shizuoka Cancer Center, 1007, Shimonakakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
3Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007, Shimonakakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.
4Shizuoka Cancer Center, Clinical Trial Coordination Office, 1007, Shimonakakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan.

Received: 25 January 2013 Accepted: 22 July 2013 Published: 23 July 2013

References

1. World Health Organization: Fact sheet N°297 (Cancer). 2012. http://www.who.int/mediacentre/factsheets/fs297/en/index.html
2. American Cancer Society: Lung Cancer (Non-small cell). 2012:1–68. http://www.cancer.org/cancer/lanuancancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer
3. Scaglotti G, Pankh P, von Pawel J, Beerna B, Fansteenkeite J, Manegold C, Setiawatowsili P, Gatarrnait J, Zikan M, Lee JS, Meenagand A, Park K, Pato S, Rokeli J, Goksel T, de Marinis F, Lâm M, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small cell lung cancer. J Clin Oncol 2008, 26:3543–3551.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006, 355:2542–2550.
5. Niho S, Kuntotta H, Nokihara H, Horai T, Ichinose Y, Hida M, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsu K, Negoro S, Yokozuma A, Kudoh S, Kitu K, Mor K, Okamoto H, Sakal H, Takeda K, Yokota S, Sato N, Fukuda M: Randomized phase II study of first line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 2012, 76:363–367.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Branningan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139.
7. Pao J, Jiai PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Nakhi K, Sasaki H, Fuji Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497–1500.
8. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947–957.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Otsuzi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinosita I, Fujita Y, Okinaga S, Hirao N, Yoshimoto K, Harada T, Oyura T, Ando M, Miyazawa H, Tanaka T, Sato Y, Hagiwara K, Mimita S, Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380–2388.
10. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felipe E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Roveri L, Illiasso A, Dani S, de Castro J, Milletta M, Reguart N, Altavilla G, Jimenez U, Provenço M, Moreno MA, Tenesa J, Muñoz-Langa J, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239–246.
11. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsutsumi J, Seto T, Satouchi M, Tada H, Hiroshima T, Asami K, Katayama N, Takada M, Yoshikoa H, Shibata K, Kudoh S, Shinizu E, Saito H, Toyooka S, Nakagawa K, Fukuda M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121–128.
12. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen VR, Tsai SF. High frequency of epidermal growth factor receptor factor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10:8195–8203.
13. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64:8919–8923.
14. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujiwasa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339–346.

15. Chou TY, Chiu CH, HW, Hsiao CY, Tseng CH, Chang KT, Chen YM, Peng RP, Tsai SF, Tsai CM: More than one tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small-cell lung cancer. Oncol Res 2005, 11:370–375.

16. Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH: Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. J Korean Med Sci 2009, 24:448–452.

17. Miyamae Y, Shimmizu K, Hiroti J, Asahi T, Tanaka K, Ogawa H, Kakegawa S, Sugano M, Nakano T, Mitani Y, Kaira K, Takeyoshi I: Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011, 25:921–928.

18. Ohtsuka K, Oinishi H, Fujiwara M, Kishino T, Matsushima S, Furuyashiki G, Takei H, Koshishi J, Goya T, Watanabe T: Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas. adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer 2007, 109:741–750.

19. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, Travis WD, Zakowski MF, Kris MG, Ladanyi M: Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/ AKT1 mutations. Clin Cancer Res 2012, 18:1167–1176.

20. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982, 31:1–24.

21. Moll R, Lowe A, Laufer J, Franke WW: Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992, 140:427–447.

22. Hatfield M, Franke WW: Pair formation and promiscuity of cytokeratins: formation in vitro of heterotypic complexes and intermediate-sized polypeptides. J Cell Biol 1983, 101:1826–1841.

23. Rastel D, Ramaekers FC, Rot MK, Oostendorp T, Huysmans A, van Muijen GN, Wagenaar SS, Vooijs GP: Pair formation and promiscuity of cytokeratin subunit 19 measured by CYFRA 21–1 level predicts survival in non-small-cell lung cancer. J Thorac Oncol 2011, 6:2076–2077.

24. Reimnuth N, Brandt B, Semik M, Kunze WP, Achaty R, Schelld H, Broermann P, Berdel WE, Mcha H, Thomas M: Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002, 36:265–270.

25. Hanagiri T, Sazaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Harumoto H, Takenoyama M, Yasumoto K, Tanaka F: Preoperative CYFRA 21–1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011, 74:112–117.

26. Chapman MH, Sandanayake NS, Andreoufa D, Dhar DK, Webster GD, Dooley JS, Pereira SP: Circulating CYFRA 21–1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol 2011, 1:6–12.

27. Suyama T, Nakajima K, Kanbe S, Tanaka N, Hara H, Ichi N: Prognostic significance of preoperative serum CYFRA 21–1 in patients with upper urinary tract urothelial carcinoma. Int J Urol 2011, 18:43–47.

28. Doveck I, Barak M, Uri N, Greenberg E: The prognostic value of the tumour marker Cyfra 21–1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 2000, 83:1696–1701.

29. Shimada H, Nabeya Y, Okamura S, Matsuzaka Y, Hayashi H, Gunji Y, Ochiai T: Prognostic significance of CYFRA 21–1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 2003, 196:573–578.

30. Bonfert JM, Gaalenstroom KN, Kenter GG, Korne CM, Hart AA, Galle MP, Hemmerth TJ, Kenemans P: Prognostic significance of fragments of cytokeratin 19 measured by Cyfra 21–1 in cervical cancer. Gynecol Oncol 1994, 55:371–375.

31. Midoung J, Deys A, Simon M, Rouzaud P, Salama G, Reyre J, Pujoion M, Carles P, Serre G: High levels of cytokeratin 19 fragments but no evidence of cytokeratin 1, 2, 10, 11, 14 or filgrin in the serum of squamous cell lung carcinoma patients. Tumour Biol 2001, 22:19–26.

32. Ramaekers F, Huysmans A, Moesker O, Kant A, Jap P, Hermans C, Vooijs P: Monoclonal antibody to keratin filaments, specific for glandular epithelia of the urinary tract urothelial carcinoma. Int J Urol 2003, 59:5–14.

33. Moll R, Franke WW, Carles P, Serre G, Hata J, Broermann P, Berdel WE, Mcha H, Thomas M: Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002, 36:265–270.

34. Hanagiri T, Sazaya M, Takenaka M, Oka S, Baba T, Shigematsu Y, Nagata Y, Shimokawa H, Harumoto H, Takenoyama M, Yasumoto K, Tanaka F: Preoperative CYFRA 21–1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer. Lung Cancer 2011, 74:112–117.

35. Chapman MH, Sandanayake NS, Andreoufa D, Dhar DK, Webster GD, Dooley JS, Pereira SP: Circulating CYFRA 21–1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer. J Clin Exp Hepatol 2011, 1:6–12.

36. Suyama T, Nakajima K, Kanbe S, Tanaka N, Hara H, Ichi N: Prognostic significance of preoperative serum CYFRA 21–1 in patients with upper urinary tract urothelial carcinoma. Int J Urol 2011, 18:43–47.

37. Doveck I, Barak M, Uri N, Greenberg E: The prognostic value of the tumour marker Cyfra 21–1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer 2000, 83:1696–1701.

38. Shimada H, Nabeya Y, Okamura S, Matsuzaka Y, Hayashi H, Gunji Y, Ochiai T: Prognostic significance of CYFRA 21–1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 2003, 196:573–578.

39. Bonfert JM, Gaalenstroom KN, Kenter GG, Korne CM, Hart AA, Galle MP, Hemmerth TJ, Kenemans P: Prognostic significance of fragments of cytokeratin 19 measured by Cyfra 21–1 in cervical cancer. Gynecol Oncol 1994, 55:371–375.

40. Midoung J, Deys A, Simon M, Rouzaud P, Salama G, Reyre J, Pujoion M, Carles P, Serre G: High levels of cytokeratin 19 fragments but no evidence of cytokeratin 1, 2, 10, 11, 14 or filgrin in the serum of squamous cell lung carcinoma patients. Tumour Biol 2001, 22:19–26.

41. Ramaekers F, Huysmans A, Moesker O, Kant A, Jap P, Hermans C, Vooijs P: Monoclonal antibody to keratin filaments, specific for glandular epithelia and their tumors. Use in surgical pathology. Lab Invest 1983, 49:353–361.

42. Kang SM, Kang HJ, Shin JH, Kim H, Shin DH, Kim SK, Kim JH, Chung KY, Kim SK, Chang J: Identical epidermal growth factor receptor mutations in adenosquamous carcinoma and squamous cell carcinoma components of adenosquamous carcinoma of the lung. Cancer 2007, 109:581–587.

43. Nishi S, Yokose T, Kadoma T, Nishiwaki Y, Mukai K: Clonal analysis of adenosquamous carcinoma of the lung. Jpn J Cancer Res 1999, 90:1244–1247.

44. Goya T, Asamura H, Yoshimura H, Kato H, Shimokawa K, Tsutsui Y, Sahara Y, Miya T, Miyaoka E: Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005, 50:227–234.

45. Gawrychowski J, Brulífski K, Malinowski E, Papla B: Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg 2005, 27:568–569.
52. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. *Cancer Sci* 2008, 99:929–935.

53. Yatabe Y, Matsuo K, Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. *J Clin Oncol* 2011, 29:2972–2977.

54. Eberhard DA, Johnson BE, Amrler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Oistand MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol* 2005, 23:5900–5909.

55. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Lacorna RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukushima M, Kris MG, Baselga J, Ochs JS, Haber DA: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. *J Clin Oncol* 2005, 23:8081–8092.

56. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kernell-Reid S, Seymour L, Shepherd FA, Tsao MS, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. *J Clin Oncol* 2008, 26:4268–4275.

57. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Takaishi N, Takada M, Yoshioka H, Shibata K, Kubof S, Shimizu E, Saito H, Toyoaka S, Nakagawa K, Fukushima M: Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). *Proc Am Soc Clin Oncol* 2012, 30:7521.

doi:10.1186/1471-2407-13-354

Cite this article as: Ono et al. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study. *BMC Cancer* 2013 13:354.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit